Earnings summaries and quarterly performance for ITCI.
Executive leadership at ITCI.
Board of directors at ITCI.
Research analysts who have asked questions during ITCI earnings calls.
Jessica Fye
JPMorgan Chase & Co.
3 questions for ITCI
Ami Fadia
Needham & Company, LLC
2 questions for ITCI
Charles Duncan
Cantor Fitzgerald & Co.
2 questions for ITCI
David Amsellem
Piper Sandler Companies
2 questions for ITCI
Andrew Tsai
Jefferies
1 question for ITCI
Ash Verma
UBS
1 question for ITCI
Corinne Johnson
Goldman Sachs
1 question for ITCI
Dena Ramadan
Bank of America
1 question for ITCI
Jeff Hung
Morgan Stanley
1 question for ITCI
Joseph Thome
TD Cowen
1 question for ITCI
Marc Goodman
Leerink Partners
1 question for ITCI
Michael DiFiore
Evercore ISI
1 question for ITCI
Michael Riad
Morgan Stanley
1 question for ITCI
Nevin Varghese
RBC Capital Markets
1 question for ITCI
Recent press releases and 8-K filings for ITCI.
- Merger Completion: On April 2, 2025, the merger was finalized, converting each common share to a cash consideration of $132.00 per share.
- Change in Control: As a result of the transaction, the company became a wholly owned subsidiary of Johnson & Johnson, with approximately $14.6 billion in consideration paid to its stockholders.
- Listing Update: The company notified Nasdaq to halt trading and initiated procedures to delist its shares and deregister under the Exchange Act.
- Governance Amendments: The company’s certificate of incorporation and bylaws were amended and restated, leading to a board reorganization with incoming directors from Merger Sub.
- Special meeting held on March 27, 2025: The company approved its Merger Agreement with Johnson & Johnson, where a special meeting of stockholders was convened.
- Merger vote details: Approximately 73.31% of outstanding shares were represented, leading to the successful adoption of both the Merger Agreement and related proposals, with the transaction expected to close on or around April 2, 2025.
- The 8-K announces the filing of a Proxy Statement and an upcoming special meeting on March 27, 2025, related to the merger with Johnson & Johnson, with stockholder eligibility as of February 13, 2025.
- Multiple litigation actions have been initiated by stockholders, including the Morgan, O’Neill, and Drulias complaints, alleging misrepresentations in the Proxy Statement disclosures.
- Supplemental disclosures include detailed valuation analyses by Centerview Partners and Jefferies, comparing ITI’s estimated per share equity value (approximately $102.90 to $127.70) to the merger consideration of $132.00 per share.
Quarterly earnings call transcripts for ITCI.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track ITCI's earnings for you
Get instant analysis when filings drop